{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:58:22Z","timestamp":1761893902730},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5819,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1093\/annonc\/mdh069","type":"journal-article","created":{"date-parts":[[2004,2,2]],"date-time":"2004-02-02T17:04:03Z","timestamp":1075741443000},"page":"283-290","source":"Crossref","is-referenced-by-count":80,"title":["Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis"],"prefix":"10.1016","volume":"15","author":[{"given":"J.","family":"Mangel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.A.","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Spaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Crump","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.L.","family":"Berinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh069_bb0010","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of two indolent lymphomas: mantle cell and marginal zone lymphoma","volume":"85","author":"Fisher","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0015","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","article-title":"Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin\u2019s lymphoma subtypes","volume":"13","author":"Teodorovic","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","article-title":"Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve prognosis","volume":"7","author":"Meusers","year":"1989","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0025","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German low-grade lymphoma study group","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0959-8049(97)10056-9","article-title":"Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients","volume":"34","author":"Oinonen","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh069_bb0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0040","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh069_bb0045","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood.V83.10.2829.2829","article-title":"Non-follicular small B-cell lymphomas: a heterogenous group of patients with distinct clinical features and outcomes","volume":"83","author":"Berger","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B","article-title":"Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group","volume":"64","author":"Weisenberger","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdh069_bb0055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1365-2141.1997.4693273.x","article-title":"The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group","volume":"99","author":"Vandenberghe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdh069_bb0060","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdh069_bb0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.1998.16.1.3","article-title":"Coiffier B. Which treatment for mantle-cell lymphoma patients in 1998?","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s002770050545","article-title":"Management of mantle cell lymphoma","volume":"78","author":"Meusers","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdh069_bb0075","first-page":"1975","article-title":"Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma","volume":"10","author":"Haas","year":"1996","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdh069_bb0080","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1023\/A:1008278605751","article-title":"Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma","volume":"8","author":"Ketterer","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0085","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1023\/A:1008251301319","article-title":"Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma","volume":"8","author":"Dreger","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.bmt.1701033","article-title":"Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy","volume":"21","author":"Kroger","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh069_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bmt.1701046","article-title":"High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin\u2019s lymphomas: a single center experience on 18 patients","volume":"21","author":"Blay","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh069_bb0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/oxfordjournals.annonc.a059156","article-title":"The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"6","author":"Stewart","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"Abstr 1915","key":"10.1093\/annonc\/mdh069_bb0115","first-page":"92","article-title":"Autologous stem cell transplantation for mantle cell lymphoma. The experience of the GEL\/TAMO Spanish cooperative group","volume":"464a","author":"Conde","year":"1998","journal-title":"Blood"},{"issue":"Abstr 1894","key":"10.1093\/annonc\/mdh069_bb0120","first-page":"92","article-title":"Autologous and allogeneic stem cell transplantation for poor-risk mantle cell lymphoma: the City of Hope experience","volume":"459a","author":"Molina","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0125","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1702135","article-title":"Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study","volume":"25","author":"Decaudin","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh069_bb0130","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Abstr 2833","key":"10.1093\/annonc\/mdh069_bb0135","first-page":"98","article-title":"Complete clinical and molecular remissions can be achieved following autologous stem cell transplantation in combination with Rituximab immunotherapy for the treatment of newly diagnosed mantle cell lymphoma","volume":"677a","author":"Mangel","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0140","first-page":"115","article-title":"Stem cell function and engraftment is not affected by \u201cin vivo purging\u201d with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin\u2019s lymphoma","volume":"26","author":"Buckstein","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0145","first-page":"1629","article-title":"Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma","volume":"61","author":"Welzel","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdh069_bb0150","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0160","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphoma","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0165","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdh069_bb0170","first-page":"836","article-title":"Prednimustine, mitoxantrone (PmM) vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin\u2019s lymphomas","volume":"10","author":"Unterhalt","year":"1996","journal-title":"Leukemia"},{"issue":"Abstr 3572","key":"10.1093\/annonc\/mdh069_bb0175","first-page":"98","article-title":"Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma \u2013 results of a prospective randomized European intergroup study","volume":"861a","author":"Hiddemann","year":"2001","journal-title":"Blood"},{"issue":"Abstr 3507","key":"10.1093\/annonc\/mdh069_bb0180","first-page":"98","volume":"844a","author":"Hiddemann","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0185","first-page":"1927","article-title":"Rituximab for the treatment of relapsing refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin\u2019s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Haematol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh069_bb0200","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of Rituximab on patients with follicular and mantle-cell lymphoma","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh069_bb0205","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Ann Oncol"},{"issue":"Abstr 3030","key":"10.1093\/annonc\/mdh069_bb0210","first-page":"98","article-title":"Mantle cell lymphoma\u2014high rates of complete remission and prolonged failure-free survival with rituxan-HyperCVAD without stem cell transplant","volume":"726a","author":"Romaguera","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0215","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh069_bb0220","first-page":"172a","article-title":"The impact of early stem cell transplantation on the prognosis of mantle cell lymphoma","volume":"94","author":"Dreger","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0225","first-page":"638a","article-title":"In vivo purging with rituximab during stem cell transplantation for indolent lymphoma","volume":"94","author":"Flinn","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0230","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin\u2019s lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0235","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"issue":"Abstr 3578","key":"10.1093\/annonc\/mdh069_bb0240","first-page":"98","article-title":"Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin\u2019s lymphomas","volume":"862a","author":"Horwitz","year":"2001","journal-title":"Blood"},{"issue":"Abstr 1655","key":"10.1093\/annonc\/mdh069_bb0245","first-page":"96","article-title":"Pulmonary complications after autologous transplantation and immunotherapy with Rituximab in patients with follicular lymphoma","volume":"383a","author":"Mangel","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh069_bb0250","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1200\/JCO.1991.9.10.1871","article-title":"Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin\u2019s disease","volume":"9","author":"Reece","year":"1991","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419656310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419656310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/2\/283\/364255\/mdh069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T21:50:32Z","timestamp":1582235432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419656310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0923753419656310"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh069","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}